Our top pick for
Nuwellis Inc is a medical devices business based in the US. Nuwellis shares (NUWE) are listed on the NASDAQ and all prices are listed in US Dollars. Nuwellis employs 64 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.06|
|52-week range||$1.86 - $12.38|
|50-day moving average||$2.52|
|200-day moving average||$3.92|
|Wall St. target price||$13.42|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.76|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||1.98%|
|1 month (2021-09-28)||-6.79%|
|3 months (2021-07-28)||-49.01%|
|6 months (2021-04-28)||-60.76%|
|1 year (2020-10-28)||-67.61%|
|2 years (2019-10-28)||121.51%|
|3 years (2018-10-26)||13.2999|
|5 years (2016-10-28)||2100.0093|
|Revenue TTM||$8.4 million|
|Gross profit TTM||$4.1 million|
|Return on assets TTM||-54.01%|
|Return on equity TTM||-97.19%|
|Market capitalisation||$20.8 million|
TTM: trailing 12 months
There are currently 101,584 Nuwellis shares held short by investors – that's known as Nuwellis's "short interest". This figure is 130.9% up from 44,002 last month.
There are a few different ways that this level of interest in shorting Nuwellis shares can be evaluated.
Nuwellis's "short interest ratio" (SIR) is the quantity of Nuwellis shares currently shorted divided by the average quantity of Nuwellis shares traded daily (recently around 298776.47058824). Nuwellis's SIR currently stands at 0.34. In other words for every 100,000 Nuwellis shares traded daily on the market, roughly 340 shares are currently held short.
However Nuwellis's short interest can also be evaluated against the total number of Nuwellis shares, or, against the total number of tradable Nuwellis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nuwellis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Nuwellis shares in existence, roughly 10 shares are currently held short) or 0.0096% of the tradable shares (for every 100,000 tradable Nuwellis shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nuwellis.
Find out more about how you can short Nuwellis stock.
We're not expecting Nuwellis to pay a dividend over the next 12 months.
Nuwellis's shares were split on a 1:30 basis on 18 October 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nuwellis shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Nuwellis shares which in turn could have impacted Nuwellis's share price.
Over the last 12 months, Nuwellis's shares have ranged in value from as little as $1.86 up to $12.3794. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nuwellis's is 1.2169. This would suggest that Nuwellis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Nuwellis, Inc. , a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.